Lucía Canedo

Lucía Canedo

Auto-generated profile, based on publicly available information

Lucía Canedo

Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA)-CONICET -Partner Institute of the Max Planck Society, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
NSNazarena E. Ferreyra Solari
Nazarena E. Ferreyra Solari
FBFiorella Sabrina Belforte
Fiorella Sabrina Belforte
LCLucía Canedo
Lucía Canedo
GVGuillermo A. Videla-Richardson
Guillermo A. Videla-Richardson
JEJoaquín M. Espinosa
Joaquín M. Espinosa
CPCarolina Perez-Castro
Carolina Perez-Castro
KANSL2 is an integral subunit of the nonspecific lethal (NSL) chromatin-modifying complex that contributes to epigenetic programs in embryonic stem cells. In this study, we report a role for KANSL2 in regulation of stemness in glioblastoma (GBM), which is characterized by heterogeneous tumor stem–like cells associated with therapy resistance and disease relapse. KANSL2 expression is upregulated in cancer cells, mainly at perivascular regions of tumors. RNAi-mediated silencing of KANSL2 in GBM cells impairs their tumorigenic capacity in mouse xenograft models. In clinical specimens, we found that expression levels of KANSL2 correlate with stemness markers in GBM stem–like cell populations. Mechanistic investigations showed that KANSL2 regulates cell self-renewal, which correlates with effects on expression of the stemness transcription factor POU5F1. RNAi-mediated silencing of POU5F1 reduced KANSL2 levels, linking these two genes to stemness control in GBM cells. Together, our findings indicate that KANSL2 acts to regulate the stem cell population in GBM, defining it as a candidate GBM biomarker for clinical use. Cancer Res; 76(18); 5383–94. ©2016 AACR.